The Estée Lauder Companies Unites the World in Hope With Its 2019 Breast Cancer Campaign
1.10.2019 15:30:00 EEST | Business Wire | Press release
Every 15 seconds, somewhere in the world, a woman is diagnosed with breast cancer.1 That’s why, since 1992, The Estée Lauder Companies has been committed to saving lives - uniting and positively impacting people everywhere in its Breast Cancer Campaign’s mission to create a breast cancer-free world. For 27 years, The Estée Lauder Companies has inspired action, funding the world’s leading research to bring us closer to a cure and bringing a global level of awareness to the disease. It’s #TimeToEndBreastCancer.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20191001005402/en/
(Photo: Business Wire)
The Estée Lauder Companies has been a leader in the global breast cancer movement since Evelyn H. Lauder co-created the Pink Ribbon and started The Breast Cancer Campaign (The Campaign) in 1992. A year later, in 1993, she founded the Breast Cancer Research Foundation® (BCRF), the highest-rated nonprofit breast cancer organization in the U.S., dedicated to advancing the world’s most promising research to eradicate breast cancer. The Campaign has raised more than $79 million to support global research, education and medical services through the collective support of consumers, employees and partners worldwide, with more than $65 million funding 260 medical research grants through BCRF. This year The Campaign aims to raise another $9 million globally.
Real impact has been made and The Campaign is proudly part of that equation. Mortality rates from breast cancer have declined by 40% among women since the late 1980’s2 and BCRF-funded researchers have been involved in every major breakthrough in breast cancer prevention, diagnosis, treatment and survivorship. Breast cancer is spoken about more openly and important messages about early detection are saving lives – five-year survival rates are better than 90% with early detection.3
William P. Lauder, Executive Chairman of The Estée Lauder Companies Inc., proudly champions The Campaign’s mission and continues to honor the legacy of his late mother, stating, “The Breast Cancer Campaign is an expression of the best of what we do as a company. My mother, Evelyn Lauder, had a vision to end breast cancer when she started The Campaign in 1992. Since then, we have been pioneers in the breast cancer movement, driven by our passionate employees, partners and consumers around the world. I am so proud that her legacy lives on as we remain committed to making sustainable investments in research, education and medical services to bring us closer to eradicating this disease.”
The Estée Lauder Companies’ commitment to support research, and all of those touched by breast cancer, remains unwavering. Breast cancer is the most common cancer in women worldwide and is increasing particularly in developing countries where the majority of cases are diagnosed in late stages.4 It is the second most common cancer overall.5 Men are also touched by the disease - their lifetime risk of getting breast cancer is about 1 in 833.6
The Campaign will continue to drive worldwide efforts aligned to its mission:
-
Launch a new social media call to action to rally supporters around the world to participate and raise funds through the simple action of drawing a Pink Ribbon on the back of their hand using pink lipstick, sharing why it’s #TimeToEndBreastCancer and posting a photo on Instagram, also with #ELCdonates
- For every public, in-feed Instagram post during the month of October featuring both #TimeToEndBreastCancer and #ELCdonates together, @esteelaudercompanies will donate $25 (a half hour of research) up to $250,000 to @bcrfcure. $250,000 will fund a one-year BCRF research grant.
- Illuminate buildings, monuments and landmarks worldwide in glowing pink lights to raise awareness of breast health– including the Empire State Building, New York City, the Eiffel Tower, Paris, and Kiyomizu-dera Temple, Kyoto
- Distribute informational brochures and pink ribbons at The Estée Lauder Companies’ beauty brand counters worldwide
- Mobilize 48,000 employees to positively impact communities and unite in action
- Drive donations to BCRF through ELCompanies.com/BreastCancerCampaign
Elizabeth Hurley, The Campaign’s longtime Global Ambassador shared, “I am honored to represent The Breast Cancer Campaign and help bring attention to the powerful work The Estée Lauder Companies does each year to unify and activate the global community around the cause. Every time someone shares with me that they got a mammogram because they heard our messages, or unfortunately tells me that they have been diagnosed with breast cancer, I’m reminded of why we must continue Evelyn’s mission. I’ve seen research we are funding in action, spoken to many leaders in the field and know how hopeful they all remain – we are making real progress towards a cure and must continue to fund that advancement!”
“The Estée Lauder Companies has long been committed to making an impact on communities around the world, and our efforts through The Breast Cancer Campaign are a reflection of that purpose and underscore the Company’s family values and culture. We will continue to strive towards fulfilling the mission of The Campaign to create a breast cancer-free world,” said Fabrizio Freda, President and Chief Executive Officer, The Estée Lauder Companies Inc.
This year, 19 of the The Estée Lauder Companies’ beauty brands will support The Campaign's mission: AERIN, Aveda, BECCA, Bobbi Brown, Bumble and bumble, Clinique, Darphin, DKNY, Donna Karan, Estée Lauder, GLAMGLOW, Jo Malone London, La Mer, Lab Series, Origins, Prescriptives, RODIN olio lusso, Smashbox, and Tom Ford Beauty. Each will contribute by selling Pink Ribbon Products or making donations to BCRF and/or other charitable organizations around the world. The assortment differs by country and organization.
The Campaign is a true testament to who we are as a company, the dedication of our people, our family values and most importantly the lives we can have a positive impact on around the world through our efforts as global citizens. It’s #TimeToEndBreastCancer.
To learn more about The Estée Lauder Companies’ Breast Cancer Campaign, visit ELCompanies.com/BreastCancerCampaign
ABOUT THE ESTÉE LAUDER COMPANIES INC.
The Estée Lauder Companies Inc. is one of the world’s leading manufacturers and marketers of quality skin care, makeup, fragrance and hair care products. The Company’s products are sold in approximately 150 countries and territories under brand names including: Estée Lauder, Aramis, Clinique, Prescriptives, Lab Series, Origins, Tommy Hilfiger, M·A·C, Kiton, La Mer, Bobbi Brown, Donna Karan New York, DKNY, Aveda, Jo Malone London, Bumble and bumble, Michael Kors, Darphin, Tom Ford, Smashbox, Ermenegildo Zegna, AERIN, Tory Burch, RODIN olio lusso, Le Labo, Editions de Parfums Frédéric Malle, GLAMGLOW, By Kilian, BECCA and Too Faced.
ELC-C
ELC-I
- Source: GLOBOCAN 2018 Breast Cancer Report, International Agency for Research on Cancer (http://gco.iarc.fr/today/data/factsheets/cancers/20-Breast-fact-sheet.pdf)
- Source: American Cancer Society, 2019 Trends in Breast Cancer Deaths (cancer.org/cancer/breast-cancer/about/how-common-is-breast-cancer.html)
- Source: American Cancer Society, 2019 Survival Rates for Breast Cancer (https://www.cancer.org/cancer/breast-cancer/understanding-a-breast-cancer-diagnosis/breast-cancer-survival-rates.html)
- Source: World Health Organization 2019, Breast Cancer: Prevention and Control (https://www.who.int/cancer/detection/breastcancer/en/index1.html)
- Source: GLOBOCAN 2018 Report via World Cancer Research Fund, Breast Cancer Statistics (https://www.wcrf.org/dietandcancer/cancer-trends/breast-cancer-statistics)
- Source: American Cancer Society 2019 Key Statistics for Breast Cancer in Men (https://www.cancer.org/cancer/breast-cancer-in-men/about/key-statistics.html)
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20191001005402/en/
Contact information
Bari Seiden-Young
The Estée Lauder Companies
212-572-4475
bseiden@estee.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
2PointZero Group Signals Global Scale With Revenue Surge to AED 21.9 Billion and Net Profit of AED 7.7 Billion in H1 202631.7.2026 14:42:00 EEST | Press release
2PointZero Group (ADX: 2POINTZERO), a leading Abu Dhabi-based investment holding firm, announced its financial results for the first half of 2026, reporting revenue of AED 21.9 billion and delivering a Group Net Profit of AED 7.7 billion. This robust performance is reflected in the Group’s adjusted EBITDA, which reached AED 5.0 billion after excluding fair value changes and one-offs. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260731538982/en/ Samia Bouazza, CEO of 2PointZero (Photo: AETOSWire) Net profit from the Group’s businesses increased by 2,301% year-on-year (YoY), driven by the consolidation of Tendam and the mega-merger to form 2PointZero Group, and growth was also supported by new investments in African financial services, entry into the European packaging markets, and steady operational progress across all verticals, bringing the total reported net profit to AED 7.7 billion. Through continued operational integr
Datroway ® Approved in the EU as Only TROP2 Directed Medicine with Overall Survival Benefit for the First-Line Treatment of Patients with Metastatic TNBC Who Are Not Candidates for Immunotherapy31.7.2026 09:30:00 EEST | Press release
Datroway® (datopotamab deruxtecan) has been approved in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The approval by the European Commission follows the positive opinionof the Committee for Medicinal Products for Human Use of the European Medicines Agency and is based on results from the TROPION-Breast02phase 3 trial, which were presented at the 2025 European Society for Medical Oncology Congress and subsequently published in Annals of Oncology. In TROPION-Breast02, which included patients with metastatic TNBC who experienced early relapse following prior treatment, Datroway demonstrated a statis
Polpharma Biologics Announces FDA and EMA Acceptance for Review of PB016 Vedolizumab Biosimilar Candidate31.7.2026 09:30:00 EEST | Press release
Polpharma Biologics International AG today announces that the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have accepted for review the Biologics License Application (BLA) and Marketing Authorisation Application (MAA), respectively, for PB016, a proposed vedolizumab biosimilar candidate to Takeda’s reference product Entyvio®* (vedolizumab) lyophilized vial for intravenous (IV) administration for the treatment of adults with moderately to severely active ulcerative colitis and Crohn's disease. The BLA and MAA acceptances represent significant milestones in Polpharma Biologics' development program and underscore the company's commitment to advancing high-quality biosimilars and expanding global access to affordable biologic medicines. "FDA and EMA acceptances for review of our IV vedolizumab biosimilar candidate mark a major achievement for Polpharma Biologics and validate our deep scientific expertise in biosimilar development and manufacturing," said
Half-Year Report on SES’s Liquidity Contract31.7.2026 08:30:00 EEST | Press release
Pursuant to the liquidity contract entered into by SES with BNP Paribas as of 7 April 2026, please see the below update on the progress of the liquidity services. When the liquidity services were implemented as of 7 April 2026, the following assets were in the liquidity account: € 2,500,000 As of 30 June 2026, the following assets appeared on the liquidity account: 228,186 shares; € 816,880. Over the period from 7 April 2026 to 30 June 2026, the following transactions were executed: 1,082 buy transactions; 1,308 sales transactions. Over this same period, the volumes traded represented: 1,093,335 shares and € 8,485,986 on the buy side; 873,399 shares and € 6,860,843 on the sell side. Follow us on: LinkedIn | Facebook | YouTube | X | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, businesses grow, and people stay connected—no matter where th
SES: Disclosure of Share Buyback Transactions31.7.2026 08:30:00 EEST | Press release
In the time period from June 2, 2026 until and including June 23, 2026, a number of 213,167 shares were bought back within the framework of the share buyback of SES to meet obligations under SES’s Equity Based Compensation Plan (EBCP). Shares were bought back as follows: Day of purchase Aggregated volume in shares Daily weighted average acquisition price of shares (EUR) Market June 2, 2026 27,097 8.8727 DXE June 2, 2026 72,903 8.8556 ENX June 5, 2026 16,624 8.3723 DXE June 5, 2026 31,510 8.4266 ENX June 15, 2026 26,451 7.8423 XPAR June 17, 2026 26,812 7.3910 XPAR June 23, 2026 11,770 7.2200 XPAR The transactions in a detailed form are published on SES’s website: https://www.ses.com/investors/shareholder-information/share-buy-backs. Follow us on: Twitter | Facebook | YouTube | LinkedIn | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, busin
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
